Key clinical point: Long-term erenumab treatment demonstrated sustained efficacy and safety in patients with chronic migraine (CM) with and without acute medication overuse (AMO), with erenumab reducing acute medication consumption and many patients moving to non-AMO status.
Major finding: Among baseline acute migraine-specific medication users at 52 weeks, the mean monthly migraine-specific medication days reduced by 7.4 (95% CI 6.4-8.3) days and 5.4 (95% CI 4.7-6.1) days in the AMO and non-AMO groups, respectively, with 66.1% of patients in the AMO group moving to the non-AMO group.
Study details: This post hoc subgroup analysis of a 52-week open-label extension study following a 12-week double-blind study included 469 patients with CM stratified by AMO status who were randomly assigned to receive placebo or erenumab (70 or 140 mg) throughout or switch from 70 to 140 mg erenumab.
Disclosures: This study was funded by Amgen Inc. Some authors declared being employees or stockholders of Amgen. The other authors declared ties with various sources, including Amgen.
Source: Tepper SJ et al. Long-term efficacy and safety of erenumab in patients with chronic migraine and acute medication overuse: A subgroup analysis. Headache. 2023;63(6):730-742 (Jun 14). Doi: 10.1111/head.14536